Abstract
A casein hydrolysis process was scaled up to produce the antihypertensive peptides α s1-CN f(90–94), with sequence RYLGY, and α s1-CN f(143–149), with sequence AYFYPEL. Previously, the hydrolysis process was optimized under food-grade conditions to obtain a maximum amount of active peptides, quantified by high-performance liquid chromatography–mass spectrometry. Ultrafiltration as a strategy for enrichment of active peptides was also evaluated. The casein-derived ingredients prepared at large scale showed potent angiotensin converting enzyme-inhibitory activity in vitro. Furthermore, these products produced a significant decrease in the systolic blood pressure of spontaneously hypertensive rats after oral administration (200–800 mg kg −1 of body weight). The active peptides RYLGY and AYFYPEL were stable during the processes of atomization, homogenization and pasteurization. This hydrolysate was incorporated into liquid yoghurt and no significant reduction of either peptide was detected during the shelf-life of the product.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.